Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA

Executive Summary

Company explored ‘a number of paths to approval’ with agency, but modest progression-free survival benefit in monotherapy treatment of NRAS-mutant melanoma appears to have doomed the new drug application, which was pulled less than two weeks before advisory committee review.

Advertisement

Related Content

US FDA Advisory Committee Drought Is Over … Unless Sponsors Are Scared Of Dark Clouds
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Opana ER Looking At REMS – Or Worse – After US FDA Panel Weighs Intravenous Abuse Risk
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel